Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle

被引：89
|
作者：
Morabito, N
Gaudio, A
Lasco, A
Atteritano, M
Pizzoleo, MA
Cincotta, M
La Rosa, M
Guarino, R
Meo, A
Frisina, N
机构：
[1] Univ Messina, Dept Internal Med, Messina, Italy
[2] Univ Messina, Dept Paediat, Messina, Italy
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2004年 / 19卷 / 05期
关键词：
thalassemia; osteoporosis; hypogonadism; osteoprotegerin; RANKL;
D O I：
10.1359/JBMR.040113
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Osteoporosis represents an important cause of morbidity in adult thalassemic patients, and its pathogenesis has not, as yet, been completely clarified. In our study, we observed that thalassemic patients showed a significantly lower OPG/RANKL ratio than normal subjects. These data are extremely important for the possible therapeutic use of RANKL antagonists such as OPG in thalassemia-induced osteoporosis.
引用
收藏
页码：722 / 727
页数：6
相关论文
共 34 条
  • [1] OSTEOPROTEGERIN AND RECEPTOR ACTIVATOR OF THE NF-κB LIGAND (RANKL) IN EGYPTIAN PATIENTS WITH THALASSEMIA-INDUCED OSTEOPOROSIS
    El Hamid, A. E. D. S. Abd
    Attia, M.
    Saad, A.
    El Nesr, M.
    Saleh, M. Hassan
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 242 - 242
  • [2] Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis
    Xu, Shengqian
    Wang, Yu
    Lu, Jingqiu
    Xu, Jianhua
    RHEUMATOLOGY INTERNATIONAL, 2012, 32 (11) : 3397 - 3403
  • [3] Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis
    Shengqian Xu
    Yu Wang
    Jingqiu Lu
    Jianhua Xu
    Rheumatology International, 2012, 32 : 3397 - 3403
  • [4] Bisphosphonates in the Treatment of Thalassemia-Induced Osteoporosis
    N. Morabito
    A. Lasco
    A. Gaudio
    A. Crisafulli
    C. Di Pietro
    A. Meo
    N. Frisina
    Osteoporosis International, 2002, 13 : 644 - 649
  • [5] Neridronate in the treatment of thalassemia-induced osteoporosis
    不详
    CALCIFIED TISSUE INTERNATIONAL, 2006, 78 : S138 - S138
  • [6] Bisphosphonates in the treatment of thalassemia-induced osteoporosis
    Morabito, N
    Lasco, A
    Gaudio, A
    Crisafulli, A
    Di Pietro, C
    Meo, A
    Frisina, N
    OSTEOPOROSIS INTERNATIONAL, 2002, 13 (08) : 644 - 649
  • [7] Osteoprotegerin and RANKL in the pathogenesis of osteoporosis in patients with thalassaemia major
    Pietrapertosa, A. C.
    Minenna, G.
    Colella, S. M.
    Santeramo, T. M.
    Renni, R.
    D'Amore, M.
    PANMINERVA MEDICA, 2009, 51 (01) : 17 - 23
  • [8] Osteoporosis and osteosclerosis in sickle cell/β-thalassemia: the role of the RANKL/osteoprotegerin axis
    Voskaridou, Ersi
    Stoupa, Eleni
    Antoniadou, Lito
    Premetis, Evangelos
    Konstantopoulos, Kostas
    Papassotiriou, Ioannis
    Terpos, Evangelos
    HAEMATOLOGICA, 2006, 91 (06) : 813 - 816
  • [9] Quantitative ultrasound of bone and clodronate effects in thalassemia-induced osteoporosis
    Pennisi, P
    Pizzarelli, G
    Spina, M
    Riccobene, S
    Fiore, CE
    JOURNAL OF BONE AND MINERAL METABOLISM, 2003, 21 (06) : 402 - 408
  • [10] Quantitative ultrasound of bone and clodronate effects in thalassemia-induced osteoporosis
    Pietra Pennisi
    Giuseppe Pizzarelli
    Massimo Spina
    Stefania Riccobene
    Carmelo Erio Fiore
    Journal of Bone and Mineral Metabolism, 2003, 21 : 402 - 408
1234